<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39448712</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>25</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>29</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>24</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Characterization of Collaborative Cross mouse founder strain CAST/EiJ as a novel model for lethal COVID-19.</ArticleTitle><Pagination><StartPage>25147</StartPage><MedlinePgn>25147</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">25147</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-024-77087-1</ELocationID><Abstract><AbstractText>Mutations in SARS-CoV-2 variants of concern (VOCs) have expanded the viral host range beyond primates, and a few other mammals, to mice, affording the opportunity to exploit genetically diverse mouse panels to model the broad spectrum of responses to infection in patient populations. Here we surveyed responses to VOC infection in genetically diverse Collaborative Cross (CC) founder strains. Infection of wild-derived CC founder strains produced a broad range of viral burden, disease susceptibility and survival, whereas most other strains were resistant to disease despite measurable lung viral titers. In particular, CAST/EiJ, a wild-derived strain, developed high lung viral burdens, more severe lung pathology than seen in other CC strains, and a dysregulated cytokine profile resulting in morbidity and mortality. These inbred mouse strains may serve as a valuable platform to evaluate therapeutic countermeasures against severe COVID-19 and other coronavirus pandemics in the future.</AbstractText><CopyrightInformation>Â© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Baker</LastName><ForeName>Candice N</ForeName><Initials>CN</Initials><AffiliationInfo><Affiliation>The Jackson Laboratory, Bar Harbor, ME, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Duso</LastName><ForeName>Debra</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Trudeau Institute, Saranac Lake, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kothapalli</LastName><ForeName>Nagarama</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Trudeau Institute, Saranac Lake, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hart</LastName><ForeName>Tricia</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Trudeau Institute, Saranac Lake, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Casey</LastName><ForeName>Sean</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Trudeau Institute, Saranac Lake, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cookenham</LastName><ForeName>Tres</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Trudeau Institute, Saranac Lake, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kummer</LastName><ForeName>Larry</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Trudeau Institute, Saranac Lake, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hvizdos</LastName><ForeName>Janine</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Trudeau Institute, Saranac Lake, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lanzer</LastName><ForeName>Kathleen</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Trudeau Institute, Saranac Lake, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vats</LastName><ForeName>Purva</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>The Jackson Laboratory, Farmington, CT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shanbhag</LastName><ForeName>Priya</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>The Jackson Laboratory, Farmington, CT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bell</LastName><ForeName>Isaac</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>The Jackson Laboratory, Farmington, CT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tighe</LastName><ForeName>Mike</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Trudeau Institute, Saranac Lake, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Travis</LastName><ForeName>Kelsey</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Trudeau Institute, Saranac Lake, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Szaba</LastName><ForeName>Frank</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Trudeau Institute, Saranac Lake, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harder</LastName><ForeName>Jeffrey M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>The Jackson Laboratory, Bar Harbor, ME, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bedard</LastName><ForeName>Olivia</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>The Jackson Laboratory, Bar Harbor, ME, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oberding</LastName><ForeName>Natalie</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Trudeau Institute, Saranac Lake, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ward</LastName><ForeName>Jerrold M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Trudeau Institute, Saranac Lake, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Adams</LastName><ForeName>Mark D</ForeName><Initials>MD</Initials><AffiliationInfo><Affiliation>The Jackson Laboratory, Farmington, CT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lutz</LastName><ForeName>Cathleen</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>The Jackson Laboratory, Bar Harbor, ME, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bradrick</LastName><ForeName>Shelton S</ForeName><Initials>SS</Initials><AffiliationInfo><Affiliation>Trudeau Institute, Saranac Lake, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reiley</LastName><ForeName>William W</ForeName><Initials>WW</Initials><AffiliationInfo><Affiliation>Trudeau Institute, Saranac Lake, NY, USA. Wreiley@trudeauinstitute.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosenthal</LastName><ForeName>Nadia A</ForeName><Initials>NA</Initials><AffiliationInfo><Affiliation>The Jackson Laboratory, Bar Harbor, ME, USA. Nadia.Rosenthal@jax.org.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Heart and Lung Institute, Imperial College London, London, UK. Nadia.Rosenthal@jax.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P40 OD011102</GrantID><Acronym>OD</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P40 OD011102</GrantID><Acronym>CD</Acronym><Agency>ODCDC CDC HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Organism" UI="C000711908">SARS-CoV-2 variants</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="UpdateOf"><RefSource>Res Sq. 2024 Jul 29:rs.3.rs-4675061. doi: 10.21203/rs.3.rs-4675061/v1</RefSource><PMID Version="1">39149485</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="Y">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000472" MajorTopicYN="N">pathogenicity</QualifierName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008168" MajorTopicYN="N">Lung</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000076724" MajorTopicYN="N">Collaborative Cross Mice</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019562" MajorTopicYN="N">Viral Load</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>25</Day><Hour>6</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>25</Day><Hour>6</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>25</Day><Hour>0</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39448712</ArticleId><ArticleId IdType="pmc">PMC11502910</ArticleId><ArticleId IdType="doi">10.1038/s41598-024-77087-1</ArticleId><ArticleId IdType="pii">10.1038/s41598-024-77087-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Fauci, A. S. &amp; Folkers, G. K. Pandemic preparedness and response: lessons from COVID-19. J. Infect. Dis.228, 422â425. 10.1093/infdis/jiad095 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37035891</ArticleId></ArticleIdList></Reference><Reference><Citation>Morse, S. S. et al. Prediction and prevention of the next pandemic zoonosis. Lancet380, 1956â1965. 10.1016/S0140-6736(12)61684-5 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3712877</ArticleId><ArticleId IdType="pubmed">23200504</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuki, K., Fujiogi, M. &amp; Koutsogiannaki, S. COVID-19 pathophysiology: A review. Clin. Immunol.215, 108427. 10.1016/j.clim.2020.108427 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7169933</ArticleId><ArticleId IdType="pubmed">32325252</ArticleId></ArticleIdList></Reference><Reference><Citation>Guan, W. J. et al. Clinical characteristics of coronavirus disease 2019 in China. N. Engl. J. Med.382, 1708â1720. 10.1056/NEJMoa2002032 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7092819</ArticleId><ArticleId IdType="pubmed">32109013</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudre, C. H. et al. Attributes and predictors of long COVID. Nat. Med.27, 626â631. 10.1038/s41591-021-01292-y (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7611399</ArticleId><ArticleId IdType="pubmed">33692530</ArticleId></ArticleIdList></Reference><Reference><Citation>Bastard, P. et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science10.1126/science.abd4585 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7857397</ArticleId><ArticleId IdType="pubmed">32972996</ArticleId></ArticleIdList></Reference><Reference><Citation>Collaborators, G. B. D. R. F. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990â2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet392, 1923â1994. 10.1016/S0140-6736(18)32225-6 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6227755</ArticleId><ArticleId IdType="pubmed">30496105</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu, R. et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell86, 367â377. 10.1016/s0092-8674(00)80110-5 (1996).</Citation><ArticleIdList><ArticleId IdType="pubmed">8756719</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayes, C. N., Imamura, M., Aikata, H. &amp; Chayama, K. Genetics of IL28B and HCVâresponse to infection and treatment. Nat. Rev. Gastroenterol. Hepatol.9, 406â417. 10.1038/nrgastro.2012.101 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22641049</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwok, A. J., Mentzer, A. &amp; Knight, J. C. Host genetics and infectious disease: new tools, insights and translational opportunities. Nat. Rev. Genet.22, 137â153. 10.1038/s41576-020-00297-6 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7716795</ArticleId><ArticleId IdType="pubmed">33277640</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou, P. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature579, 270â273. 10.1038/s41586-020-2012-7 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7095418</ArticleId><ArticleId IdType="pubmed">32015507</ArticleId></ArticleIdList></Reference><Reference><Citation>Letko, M., Marzi, A. &amp; Munster, V. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nat. Microbiol.5, 562â569. 10.1038/s41564-020-0688-y (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7095430</ArticleId><ArticleId IdType="pubmed">32094589</ArticleId></ArticleIdList></Reference><Reference><Citation>Dinnon, K. H. 3rd. et al. A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures. Nature586, 560â566. 10.1038/s41586-020-2708-8 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8034761</ArticleId><ArticleId IdType="pubmed">32854108</ArticleId></ArticleIdList></Reference><Reference><Citation>Tseng, C. T. et al. Severe acute respiratory syndrome coronavirus infection of mice transgenic for the human Angiotensin-converting enzyme 2 virus receptor. J. Virol.81, 1162â1173. 10.1128/JVI.01702-06 (2007).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1797529</ArticleId><ArticleId IdType="pubmed">17108019</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang, R. D. et al. Pathogenesis of SARS-CoV-2 in transgenic mice expressing human angiotensin-converting enzyme 2. Cell182, 50-58.e58. 10.1016/j.cell.2020.05.027 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7241398</ArticleId><ArticleId IdType="pubmed">32516571</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun, S. H. et al. A mouse model of SARS-CoV-2 infection and pathogenesis. Cell Host Microbe28, 124-133.e124. 10.1016/j.chom.2020.05.020 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7250783</ArticleId><ArticleId IdType="pubmed">32485164</ArticleId></ArticleIdList></Reference><Reference><Citation>Robertson, S. J. et al. Genetically diverse mouse models of SARS-CoV-2 infection reproduce clinical variation in type I interferon and cytokine responses in COVID-19. Nat. Commun.14, 4481. 10.1038/s41467-023-40076-5 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10368652</ArticleId><ArticleId IdType="pubmed">37491352</ArticleId></ArticleIdList></Reference><Reference><Citation>Leist, S. R. &amp; Baric, R. S. Giving the genes a shuffle: using natural variation to understand host genetic contributions to viral infections. Trends Genet.34, 777â789. 10.1016/j.tig.2018.07.005 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7114642</ArticleId><ArticleId IdType="pubmed">30131185</ArticleId></ArticleIdList></Reference><Reference><Citation>Stolp, B. et al. SARS-CoV-2 variants of concern display enhanced intrinsic pathogenic properties and expanded organ tropism in mouse models. Cell Rep.38, 110387. 10.1016/j.celrep.2022.110387 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8795826</ArticleId><ArticleId IdType="pubmed">35134331</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, R. et al. Analysis of SARS-CoV-2 variant mutations reveals neutralization escape mechanisms and the ability to use ACE2 receptors from additional species. Immunity54, 1611-1621.e1615. 10.1016/j.immuni.2021.06.003 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8185182</ArticleId><ArticleId IdType="pubmed">34166623</ArticleId></ArticleIdList></Reference><Reference><Citation>Winkler, E. S. et al. SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function. Nat. Immunol.21, 1327â1335. 10.1038/s41590-020-0778-2 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7578095</ArticleId><ArticleId IdType="pubmed">32839612</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumari, P. et al. Neuroinvasion and encephalitis following intranasal inoculation of SARS-CoV-2 in K18-hACE2 mice. Viruses10.3390/v13010132 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7832889</ArticleId><ArticleId IdType="pubmed">33477869</ArticleId></ArticleIdList></Reference><Reference><Citation>Rizvi, Z. A. et al. Omicron sub-lineage BA.5 infection results in attenuated pathology in hACE2 transgenic mice. Commun. Biol.6, 935. 10.1038/s42003-023-05263-6 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10499788</ArticleId><ArticleId IdType="pubmed">37704701</ArticleId></ArticleIdList></Reference><Reference><Citation>Earl, P. L., Americo, J. L. &amp; Moss, B. Lethal monkeypox virus infection of CAST/EiJ mice is associated with a deficient gamma interferon response. J. Virol.86, 9105â9112. 10.1128/JVI.00162-12 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3416162</ArticleId><ArticleId IdType="pubmed">22696658</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgan, E. L. &amp; Weigle, W. O. The immune response in aged C57BL/6 mice. II. Characterization and reversal of a defect in the ability of aged spleen cells to respond to the adjuvant properties of Fc fragments. J. Immunol.129, 36â39 (1982).</Citation><ArticleIdList><ArticleId IdType="pubmed">6979569</ArticleId></ArticleIdList></Reference><Reference><Citation>Gagliardi, M. C., Tieri, P., Ortona, E. &amp; Ruggieri, A. ACE2 expression and sex disparity in COVID-19. Cell Death Discov.6, 37. 10.1038/s41420-020-0276-1 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7248455</ArticleId><ArticleId IdType="pubmed">32499922</ArticleId></ArticleIdList></Reference><Reference><Citation>Ge, D. et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature461, 399â401. 10.1038/nature08309 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19684573</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas, D. L. et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature461, 798â801. 10.1038/nature08463 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3172006</ArticleId><ArticleId IdType="pubmed">19759533</ArticleId></ArticleIdList></Reference><Reference><Citation>Galvani, A. P. &amp; Novembre, J. The evolutionary history of the CCR5-Delta32 HIV-resistance mutation. Microbes Infect.7, 302â309. 10.1016/j.micinf.2004.12.006 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15715976</ArticleId></ArticleIdList></Reference><Reference><Citation>Niemi, M. E. K., Daly, M. J. &amp; Ganna, A. The human genetic epidemiology of COVID-19. Nat. Rev. Genet.23, 533â546. 10.1038/s41576-022-00478-5 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9060414</ArticleId><ArticleId IdType="pubmed">35501396</ArticleId></ArticleIdList></Reference><Reference><Citation>Akira, S., Uematsu, S. &amp; Takeuchi, O. Pathogen recognition and innate immunity. Cell124, 783â801. 10.1016/j.cell.2006.02.015 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16497588</ArticleId></ArticleIdList></Reference><Reference><Citation>Ball, R. L. et al. GenomeMUSter mouse genetic variation service enables multi-trait, multi-population data integration and analyses. bioRxiv10.1101/2023.08.08.552506 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10680853</ArticleId><ArticleId IdType="pubmed">38014333</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng, X. et al. Unique signatures of long noncoding RNA expression in response to virus infection and altered innate immune signaling. mBio10.1128/mBio.00206-10 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2962437</ArticleId><ArticleId IdType="pubmed">20978541</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng, X. et al. Integrative deep sequencing of the mouse lung transcriptome reveals differential expression of diverse classes of small RNAs in response to respiratory virus infection. mBio10.1128/mBio.00198-11 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3221602</ArticleId><ArticleId IdType="pubmed">22086488</ArticleId></ArticleIdList></Reference><Reference><Citation>Gralinski, L. E. et al. Genome wide identification of SARS-CoV susceptibility loci using the Collaborative Cross. PLoS Genet.11, e1005504. 10.1371/journal.pgen.1005504 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4599853</ArticleId><ArticleId IdType="pubmed">26452100</ArticleId></ArticleIdList></Reference><Reference><Citation>Gralinski, L. E. et al. Allelic variation in the toll-like receptor adaptor protein Ticam2 contributes to SARS-coronavirus pathogenesis in mice. G37, 1653â1663. 10.1534/g3.117.041434 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5473747</ArticleId><ArticleId IdType="pubmed">28592648</ArticleId></ArticleIdList></Reference><Reference><Citation>Graham, J. B. et al. Baseline T cell immune phenotypes predict virologic and disease control upon SARS-CoV infection in Collaborative Cross mice. PLoS Pathog.17, e1009287. 10.1371/journal.ppat.1009287 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7875398</ArticleId><ArticleId IdType="pubmed">33513210</ArticleId></ArticleIdList></Reference><Reference><Citation>Schafer, A. et al. A multitrait locus regulates sarbecovirus pathogenesis. mBio13, e0145422. 10.1128/mbio.01454-22 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9426612</ArticleId><ArticleId IdType="pubmed">35862771</ArticleId></ArticleIdList></Reference><Reference><Citation>Bottomly, D. et al. Expression quantitative trait Loci for extreme host response to influenza a in pre-collaborative cross mice. G32, 213â221. 10.1534/g3.111.001800 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3284329</ArticleId><ArticleId IdType="pubmed">22384400</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferris, M. T. et al. Modeling host genetic regulation of influenza pathogenesis in the collaborative cross. PLoS Pathog.9, e1003196. 10.1371/journal.ppat.1003196 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3585141</ArticleId><ArticleId IdType="pubmed">23468633</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiong, H. et al. Genomic profiling of collaborative cross founder mice infected with respiratory viruses reveals novel transcripts and infection-related strain-specific gene and isoform expression. G34, 1429â1444. 10.1534/g3.114.011759 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4132174</ArticleId><ArticleId IdType="pubmed">24902603</ArticleId></ArticleIdList></Reference><Reference><Citation>Leist, S. R. et al. Influenza H3N2 infection of the collaborative cross founder strains reveals highly divergent host responses and identifies a unique phenotype in CAST/EiJ mice. BMC Genomics17, 143. 10.1186/s12864-016-2483-y (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4769537</ArticleId><ArticleId IdType="pubmed">26921172</ArticleId></ArticleIdList></Reference><Reference><Citation>Maurizio, P. L. et al. Bayesian diallel analysis reveals Mx1-dependent and Mx1-independent effects on response to influenza A virus in mice. G38, 427â445. 10.1534/g3.117.300438 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5919740</ArticleId><ArticleId IdType="pubmed">29187420</ArticleId></ArticleIdList></Reference><Reference><Citation>Graham, J. B. et al. Immune predictors of mortality after ribonucleic acid virus infection. J. Infect. Dis.221, 882â889. 10.1093/infdis/jiz531 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7107456</ArticleId><ArticleId IdType="pubmed">31621854</ArticleId></ArticleIdList></Reference><Reference><Citation>Rasmussen, A. L. et al. Host genetic diversity enables Ebola hemorrhagic fever pathogenesis and resistance. Science346, 987â991. 10.1126/science.1259595 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4241145</ArticleId><ArticleId IdType="pubmed">25359852</ArticleId></ArticleIdList></Reference><Reference><Citation>Price, A. et al. Transcriptional correlates of tolerance and lethality in mice predict ebola virus disease patient outcomes. Cell Rep.30, 1702-1713.e1706. 10.1016/j.celrep.2020.01.026 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11062563</ArticleId><ArticleId IdType="pubmed">32049004</ArticleId></ArticleIdList></Reference><Reference><Citation>Graham, J. B. et al. Genetic diversity in the collaborative cross model recapitulates human West Nile virus disease outcomes. mBio6, e00493-00415. 10.1128/mBio.00493-15 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4436067</ArticleId><ArticleId IdType="pubmed">25944860</ArticleId></ArticleIdList></Reference><Reference><Citation>Graham, J. B. et al. A mouse model of chronic West Nile Virus disease. PLoS Pathog.12, e1005996. 10.1371/journal.ppat.1005996 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5091767</ArticleId><ArticleId IdType="pubmed">27806117</ArticleId></ArticleIdList></Reference><Reference><Citation>Green, R. et al. Oas1b-dependent immune transcriptional profiles of West Nile Virus infection in the Collaborative Cross. G37, 1665â1682. 10.1534/g3.117.041624 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5473748</ArticleId><ArticleId IdType="pubmed">28592649</ArticleId></ArticleIdList></Reference><Reference><Citation>Graham, J. B. et al. Correlation of regulatory T cell numbers with disease tolerance upon virus infection. Immunohorizons5, 157â169. 10.4049/immunohorizons.2100009 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8281504</ArticleId><ArticleId IdType="pubmed">33893179</ArticleId></ArticleIdList></Reference><Reference><Citation>Brinkmeyer-Langford, C. L. et al. Host genetic background influences diverse neurological responses to viral infection in mice. Sci. Rep.7, 12194. 10.1038/s41598-017-12477-2 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5610195</ArticleId><ArticleId IdType="pubmed">28939838</ArticleId></ArticleIdList></Reference><Reference><Citation>Eldridge, R. et al. Antecedent presentation of neurological phenotypes in the collaborative cross reveals four classes with complex sex-dependencies. Sci. Rep.10, 7918. 10.1038/s41598-020-64862-z (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7220920</ArticleId><ArticleId IdType="pubmed">32404926</ArticleId></ArticleIdList></Reference><Reference><Citation>Lawley, K. S. et al. Host genetic diversity drives variable central nervous system lesion distribution in chronic phase of Theilerâs Murine Encephalomyelitis Virus (TMEV) infection. PLoS ONE16, e0256370. 10.1371/journal.pone.0256370 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8378701</ArticleId><ArticleId IdType="pubmed">34415947</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez Gomez, A. A. et al. Genetic and immunological contributors to virus-induced paralysis. Brain Behav. Immun. Health18, 100395. 10.1016/j.bbih.2021.100395 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8645428</ArticleId><ArticleId IdType="pubmed">34917987</ArticleId></ArticleIdList></Reference><Reference><Citation>Lawley, K. S. et al. Viral clearance and neuroinflammation in acute TMEV infection vary by host genetic background. Int. J. Mol. Sci.10.3390/ijms231810482 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9501595</ArticleId><ArticleId IdType="pubmed">36142395</ArticleId></ArticleIdList></Reference><Reference><Citation>Oldstone, M. B. A. et al. Lymphocytic choriomeningitis virus Clone 13 infection causes either persistence or acute death dependent on IFN-1, cytotoxic T lymphocytes (CTLs), and host genetics. Proc. Natl. Acad. Sci. USA115, E7814âE7823. 10.1073/pnas.1804674115 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6099862</ArticleId><ArticleId IdType="pubmed">30061383</ArticleId></ArticleIdList></Reference><Reference><Citation>Manet, C. et al. Genetic diversity of collaborative cross mice controls viral replication, clinical severity, and brain pathology induced by Zika virus infection, independently of Oas1b. J. Virol.10.1128/JVI.01034-19 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7000970</ArticleId><ArticleId IdType="pubmed">31694939</ArticleId></ArticleIdList></Reference><Reference><Citation>Cartwright, H. N. et al. Genetic diversity of collaborative cross mice enables identification of novel rift valley fever virus encephalitis model. PLoS Pathog.18, e1010649. 10.1371/journal.ppat.1010649 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9282606</ArticleId><ArticleId IdType="pubmed">35834486</ArticleId></ArticleIdList></Reference><Reference><Citation>Jasperse, B. A. et al. Neuroinvasive flavivirus pathogenesis is restricted by host genetic factors in collaborative cross mice, independently of Oas1b. J. Virol.97, e0071523. 10.1128/jvi.00715-23 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10373552</ArticleId><ArticleId IdType="pubmed">37310228</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown, A. J. et al. Host genetic variation guides hepacivirus clearance, chronicity, and liver fibrosis in mice. Hepatology79, 183â197. 10.1097/HEP.0000000000000547 (2024).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10718216</ArticleId><ArticleId IdType="pubmed">37540195</ArticleId></ArticleIdList></Reference><Reference><Citation>Noll, K. E. et al. Complex genetic architecture underlies regulation of influenza-A-virus-specific antibody responses in the collaborative cross. Cell Rep.31, 107587. 10.1016/j.celrep.2020.107587 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7195006</ArticleId><ArticleId IdType="pubmed">32348764</ArticleId></ArticleIdList></Reference><Reference><Citation>Hou, Y. J. et al. SARS-CoV-2 reverse genetics reveals a variable infection gradient in the respiratory tract. Cell182, 429-446.e414. 10.1016/j.cell.2020.05.042 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7250779</ArticleId><ArticleId IdType="pubmed">32526206</ArticleId></ArticleIdList></Reference><Reference><Citation>Laing, A. G. et al. A dynamic COVID-19 immune signature includes associations with poor prognosis. Nat. Med.26, 1623â1635. 10.1038/s41591-020-1038-6 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32807934</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorward, D. A. et al. Tissue-specific immunopathology in fatal COVID-19. Am. J. Respir. Crit. Care Med.203, 192â201. 10.1164/rccm.202008-3265OC (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7874430</ArticleId><ArticleId IdType="pubmed">33217246</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen, S. T. et al. A shift in lung macrophage composition is associated with COVID-19 severity and recovery. Sci. Transl. Med.14, eabn5168. 10.1126/scitranslmed.abn5168 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10117220</ArticleId><ArticleId IdType="pubmed">36103512</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann, M. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell181, 271-280.e278. 10.1016/j.cell.2020.02.052 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7102627</ArticleId><ArticleId IdType="pubmed">32142651</ArticleId></ArticleIdList></Reference><Reference><Citation>Ziegler, C. G. K. et al. SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues. Cell181, 1016-1035.e1019. 10.1016/j.cell.2020.04.035 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7252096</ArticleId><ArticleId IdType="pubmed">32413319</ArticleId></ArticleIdList></Reference><Reference><Citation>Owen, D. R. et al. An oral SARS-CoV-2 M(pro) inhibitor clinical candidate for the treatment of COVID-19. Science374, 1586â1593. 10.1126/science.abl4784 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34726479</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>